B族链球菌病感染新生儿结局分析及检测治疗进展

Progress in the Outcome Analysis, Detection and Treatment of Group B Streptococcal Disease Infected Newborns

尽管近年来B族链球菌(group B streptococcus GBS)感染在治疗和预防方面取得了显著进步,但GBS感染仍然是重要的公共卫生问题,是导致新生儿不良结局的重要原因。目前GBS疫苗作为预防GBS感染的理想策略正处于研发阶段,部分疫苗已进入临床试验阶段。本文综述GBS感染患儿的发病率、不良结局、血清型、抗生素使用情况、耐药性和检测方法研究进展,为GBS感染患儿临床诊治,更准确的检测和疫苗的进一步研发提供参考,以期预防无法通过现有的产时抗生素(intrapartum antibiotic prophylaxis, IAP)治疗策略加以预防的婴儿GBS疾病。

Although in recent years, the treatment and prevention of group B streptococcus (GBS) infection has made significant progress, but still GBS infection is an important public health problem, and is an important reason for adverse outcomes in newborns. The GBS vaccines, as an ideal strategy to prevent the GES infection, is in the development stage;some vaccines have entered clinical trials. This article reviews the research progress of incidence, adverse outcomes, serotypes, antibiotic use, drug resistance and detection methods in children with GBS infection, to provide reference for clinical diagnosis and treatment of children with GBS infection, more accurate detection and further development of vaccines, in order to prevent GBS diseases in infants that cannot be prevented by existing intrapartum antibiotic prophylaxis (IAP) treatment strategies.